|
|
Blood, 15 January 2006, Vol. 107, No. 2, pp. 752-759.
Prepublished online as a Blood First Edition Paper on September 27, 2005; DOI 10.1182/blood-2005-07-3022.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects
Karoline V. Gleixner,
Matthias Mayerhofer,
Karl J. Aichberger,
Sophia Derdak,
Karoline Sonneck,
Alexandra Böhm,
Alexander Gruze,
Puchit Samorapoompichit,
Paul W. Manley,
Doriano Fabbro,
Winfried F. Pickl,
Christian Sillaber, and
Peter Valent
From the Department of Internal Medicine I, Division of Hematology and Hemostaseology, Center of Excellence in Clinical and Experimental Oncology (CLEXO), Institute of Immunology, and Institute of Histology and Embryology, Medical University of Vienna, Austria; and Novartis Pharma, Basel, Switzerland.
In most patients with systemic mastocytosis (SM), including aggressive SM and mast cell leukemia (MCL), neoplastic cells express the oncogenic KIT mutation D816V. KIT D816V is associated with constitutive tyrosine kinase (TK) activity and thus represents an attractive drug target. However, imatinib and most other TK inhibitors fail to block the TK activity of KIT D816V. We show that the novel TK-targeting drugs PKC412 and AMN107 counteract TK activity of D816V KIT and inhibit the growth of Ba/F3 cells with doxycycline-inducible expression of KIT D816V as well as the growth of primary neoplastic mast cells and HMC-1 cells harboring this KIT mutation. PKC412 was a superior agent with median inhibitory concentration (IC50) values of 50 to 250 nM without differences seen between HMC-1 cells exhibiting or lacking KIT D816V. By contrast, AMN107 exhibited more potent effects in KIT D816V- HMC-1 cells. Corresponding results were obtained with Ba/F3 cells exhibiting wild-type or D816V-mutated KIT. The growth-inhibitory effects of PKC412 and AMN107 on HMC-1 cells were associated with induction of apoptosis and down-regulation of CD2 and CD63. PKC412 was found to cooperate with AMN107, imatinib, and cladribine (2CdA) in producing growth inhibition in HMC-1, but synergistic drug interactions were observed only in cells lacking KIT D816V. Together, PKC412 and AMN107 represent promising novel agents for targeted therapy of SM. (Blood. 2006;107: 752-759)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
N. Harir, C. Boudot, K. Friedbichler, K. Sonneck, R. Kondo, S. Martin-Lanneree, L. Kenner, M. Kerenyi, S. Yahiaoui, V. Gouilleux-Gruart, et al.
Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade
Blood,
September 15, 2008;
112(6):
2463 - 2473.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Amstutz, M. Wachtel, H. Troxler, P. Kleinert, M. Ebauer, T. Haneke, C. Oehler-Janne, D. Fabbro, F. K. Niggli, and B. W. Schafer
Phosphorylation Regulates Transcriptional Activity of PAX3/FKHR and Reveals Novel Therapeutic Possibilities
Cancer Res.,
May 15, 2008;
68(10):
3767 - 3776.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Mayerhofer, K. V. Gleixner, A. Hoelbl, S. Florian, G. Hoermann, K. J. Aichberger, M. Bilban, H. Esterbauer, M.-T. Krauth, W. R. Sperr, et al.
Unique Effects of KIT D816V in BaF3 Cells: Induction of Cluster Formation, Histamine Synthesis, and Early Mast Cell Differentiation Antigens
J. Immunol.,
April 15, 2008;
180(8):
5466 - 5476.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Kneidinger, U. Schmidt, U. Rix, K. V. Gleixner, A. Vales, C. Baumgartner, C. Lupinek, M. Weghofer, K. L. Bennett, H. Herrmann, et al.
The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils
Blood,
March 15, 2008;
111(6):
3097 - 3107.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi, S. Verstovsek, and A. Pardanani
How we diagnose and treat WHO-defined systemic mastocytosis in adults
Haematologica,
January 1, 2008;
93(1):
6 - 9.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. M. Jensen, M. A. Beaven, S. Iwaki, D. D. Metcalfe, and A. M. Gilfillan
Concurrent Inhibition of Kit- and Fc{epsilon}RI-Mediated Signaling: Coordinated Suppression of Mast Cell Activation
J. Pharmacol. Exp. Ther.,
January 1, 2008;
324(1):
128 - 138.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Voisset, S. Lopez, P. Dubreuil, and P. De Sepulveda
The tyrosine kinase FES is an essential effector of KITD816V proliferation signal
Blood,
October 1, 2007;
110(7):
2593 - 2599.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Munugalavadla, E. C. Sims, J. Borneo, R. J. Chan, and R. Kapur
Genetic and pharmacologic evidence implicating the p85{alpha}, but not p85{beta}, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis
Blood,
September 1, 2007;
110(5):
1612 - 1620.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. F. Peterson, A. Boyapati, E.-Y. Ahn, J. R. Biggs, A. J. Okumura, M.-C. Lo, M. Yan, and D.-E. Zhang
Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts
Blood,
August 1, 2007;
110(3):
799 - 805.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. J. Aichberger, M. Mayerhofer, K. V. Gleixner, M.-T. Krauth, A. Gruze, W. F. Pickl, V. Wacheck, E. Selzer, L. Mullauer, H. Agis, et al.
Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412
Blood,
April 1, 2007;
109(7):
3031 - 3041.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. G. Roberts, A. F. Odell, E. M. Byrnes, R. M. Baleato, R. Griffith, A. B. Lyons, and L. K. Ashman
Resistance to c-KIT kinase inhibitors conferred by V654A mutation
Mol. Cancer Ther.,
March 1, 2007;
6(3):
1159 - 1166.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Pan, A. Quintas-Cardama, H. M. Kantarjian, C. Akin, T. Manshouri, P. Lamb, J. E. Cortes, A. Tefferi, F. J. Giles, and S. Verstovsek
EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation
Blood,
January 1, 2007;
109(1):
315 - 322.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. J. Aichberger, M. Mayerhofer, A. Vales, M.-T. Krauth, K. V. Gleixner, M. Bilban, H. Esterbauer, K. Sonneck, S. Florian, S. Derdak, et al.
The CML-related oncoprotein BCR/ABL induces expression of histidine decarboxylase (HDC) and the synthesis of histamine in leukemic cells
Blood,
November 15, 2006;
108(10):
3538 - 3547.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. L. Corless, P. Harrell, M. Lacouture, T. Bainbridge, C. Le, K. Gatter, C. White Jr, S. Granter, and M. C. Heinrich
Allele-Specific Polymerase Chain Reaction for the Imatinib-Resistant KIT D816V and D816F Mutations in Mastocytosis and Acute Myelogenous Leukemia
J. Mol. Diagn.,
November 1, 2006;
8(5):
604 - 612.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Akin
Molecular Diagnosis of Mast Cell Disorders: A Paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology
J. Mol. Diagn.,
September 1, 2006;
8(4):
412 - 419.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Paschka, G. Marcucci, A. S. Ruppert, K. Mrozek, H. Chen, R. A. Kittles, T. Vukosavljevic, D. Perrotti, J. W. Vardiman, A. J. Carroll, et al.
Adverse Prognostic Significance of KIT Mutations in Adult Acute Myeloid Leukemia With inv(16) and t(8;21): A Cancer and Leukemia Group B Study
J. Clin. Oncol.,
August 20, 2006;
24(24):
3904 - 3911.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Gabillot-Carre, Y. Lepelletier, M. Humbert, P. de Sepuvelda, N. B. Hamouda, J. P. Zappulla, R. Liblau, A. Ribadeau-Dumas, F. Machavoine, S. Letard, et al.
Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells
Blood,
August 1, 2006;
108(3):
1065 - 1072.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
